Method and Compositions for Treating Viral Infection
AssigneePhoenix Biotechnology, Inc.
InventorsRobert A. NEWMAN, Otis C. ADDINGTON
Life of this patent
Estimating the term…
Abstract
A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
Claims33
1) A method of treating viral infection in a subject in need thereof, the method comprising administering to the subject one or more doses of an antiviral composition comprising oleandrin, wherein said viral infection is caused by a positive-sense single-stranded enveloped RNA virus ((+)-ss-eRNA-V).
2) A prophylactic method of treating a subject at risk of contracting a viral infection, the method comprising chronically administering to the subject one or more doses of an antiviral composition on a recurring basis over an extended treatment period prior to the subject contracting the viral infection, thereby preventing the subject from contracting the viral infection;
- wherein the antiviral composition comprises oleandrin, and wherein said viral infection is caused by a positive-sense single-stranded enveloped RNA virus ((+)-ss-eRNA-V).
4) The method according to any one of the above claims, wherein said antiviral composition comprises a combination of oleandrin and at least two triterpenes selected from the group consisting of oleanolic acid (free acid, salt, or prodrug), ursolic acid (free acid, salt, or prodrug), betulinic acid (free acid, salt, or prodrug).
9) The method according to any one of the above claims, wherein the viral titre in the subject's blood or plasma is reduced or does not increase as a result of the treatment.
10) The method according to any one of the above claims, wherein the administration is systemic, parenteral, buccal, enteral, intramuscular, subdermal, sublingual, peroral, oral, or a combination thereof.
11) The method according to any one of the above claims, wherein one or more doses are administered on a daily, weekly or monthly basis.
12) The method according to any one of the above claims, wherein said antiviral composition is administered immediately after infection or any time within one day to 5 days after infection or at the earliest time after definite diagnosis of infection with virus.
13) The method according to any one of the above claims, wherein a dose comprises about 100-1000 mg or about 100-1000 microg of antiviral composition per Kg of body weight of said subject.
14) The method according to any one of the above claims, wherein the amount of oleandrin as part of said composition administered per day is selected from the group consisting of 140 microg to 315 microg, 20 microg to 750 microg, 12 microg to 300 microg, 12 microg to 120 microg, 0.01 microg to 100 mg, 0.01 microg to 100 microg, about 0.5 to about 100 microg, about 1 to about 80 microg, about 1.5 to about 60 microg, about 1.8 to about 60 microg, or about 1.8 to about 40 microg.
15) The method according to any one of the above claims, wherein a dose of said antiviral composition is administered twice daily or about every 12 hours, and the amount of oleandrin in said dose is about 0.25 to about 50 microg or about 0.9 to 5 microg.
16) The method according to any one of the above claims, wherein a dose of said antiviral composition comprises about 0.05-0.5 mg/kg/day, about 0.05-0.35 mg/kg/day, about 0.05-0.22 mg/kg/day, about 0.05-0.4 mg/kg/day, about 0.05-0.3 mg/kg/day, about 0.05-0.5 microg/kg/day, about 0.05-0.35 microg/kg/day, about 0.05-0.22 microg/kg/day, about 0.05-0.4 microg/kg/day, or about 0.05-0.3 microg/kg/day, based upon the unit amount of antiviral composition per kg of body weight of subject per day.
20) The method according to any one of the above claims, wherein said antiviral composition comprises an extract of plant material from Nerium species and said extract comprising at least oleandrin and said at least two triterpenes.
24) The method according to any one of the above claims, wherein following administration of said one or more doses, the plasma concentration of oleandrin in said subject is in the range of about 0.05 to about 2 ng/ml, about 0.005 to about 10 ng/mL, about 0.005 to about 8 ng/mL, about 0.01 to about 7 ng/mL, about 0.02 to about 7 ng/mL, about 0.03 to about 6 ng/mL, about 0.04 to about 5 ng/mL, or about 0.05 to about 2.5 ng/mL, in terms of the amount of oleandrin per mL of plasma.
25) The method according to any one of the above claims, wherein said antiviral composition is administered as primary antiviral therapy, adjunct antiviral therapy, or co-antiviral therapy.
26) The method according to any one of the above claims, wherein said administration comprises separate administration or coadministration of said antiviral composition with at least one other antiviral composition or with at least one other composition for treating symptoms associated with said viral infection.
28) A method of treating viral infection in a subject in need thereof, the method comprising administering to the subject one or more doses of an antiviral composition comprising a combination of oleandrin and at least two triterpenes selected from the group consisting of oleanolic acid (free acid, salt, or prodrug), ursolic acid (free acid, salt, or prodrug), betulinic acid (free acid, salt, or prodrug), wherein said viral infection is caused by a positive-sense single-stranded enveloped RNA virus ((+)-ss-eRNA-V), wherein
- a dose comprises about 100-1000 mg or about 100-1000 microg of antiviral composition per Kg of body weight of said subject;
- or the amount of oleandrin administered per day is selected from the group consisting of 140 microg to 315 microg, 20 microg to 750 microg, 12 microg to 300 microg, 12 microg to 120 microg, 0.01 microg to 100 mg, 0.01 microg to 100 microg, about 0.5 to about 100 microg, about 1 to about 80 microg, about 1.5 to about 60 microg, about 1.8 to about 60 microg, or about 1.8 to about 40 microg;
- or a dose of said antiviral composition comprises about 0.05-0.5 mg/kg/day, about 0.05-0.35 mg/kg/day, about 0.05-0.22 mg/kg/day, about 0.05-0.4 mg/kg/day, about 0.05-0.3 mg/kg/day, about 0.05-0.5 microg/kg/day, about 0.05-0.35 microg/kg/day, about 0.05-0.22 microg/kg/day, about 0.05-0.4 microg/kg/day, or about 0.05-0.3 microg/kg/day, based upon the unit amount of antiviral composition per kg of body weight of subject per day;
- and
- following administration of said one or more doses, the plasma concentration of oleandrin in said subject is in the range of about 0.05 to about 2 ng/ml, about 0.005 to about 10 ng/mL, about 0.005 to about 8 ng/mL, about 0.01 to about 7 ng/mL, about 0.02 to about 7 ng/mL, about 0.03 to about 6 ng/mL, about 0.04 to about 5 ng/mL, or about 0.05 to about 2.5 ng/mL, in terms of the amount of oleandrin per mL of plasma.
Dependencies are inferred from the claim text.